Why ReShape Lifesciences Stock Is Ripping Higher
Portfolio Pulse from Erica Kollmann
ReShape Lifesciences, Inc. (NASDAQ:RSLS) stock surged after the company announced FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. The stock experienced heavy trading volume, with over 101 million shares traded, far exceeding its 100-day average. The stock is currently trading above its 50-day moving average but below its 52-week high.
December 13, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ReShape Lifesciences stock has seen a significant increase following FDA approval for its Lap-Band 2.0 FLEX, with an 85.1% rise to 46 cents and trading volume massively surpassing the average.
The FDA approval is a significant positive catalyst for ReShape Lifesciences as it allows the company to market its new product. The surge in stock price and trading volume reflects investor optimism about the potential market impact of the Lap-Band 2.0 FLEX. The stock's performance relative to its moving averages indicates increased investor interest and potential for continued momentum in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100